Wellbeing Digital Sciences Subsidiary IRP Health Receives Approval From Veterans Affairs Canada for Reactivation Program
March 3, 2022
Ryan Allway March 3rd, 2022 Psychedelics, Top News The Company’s Receipt of Approval for the Multidisciplinary “Reactivation” Program Designed by its Wholly Owned Subsidiary is a Major Milestone That is Expected to Benefit Veterans and First Responders for the Foreseeable Future VANCOUVER, British Columbia, March 03, 2022 (GLOBE NEWSWIRE)... Read more
Ryan Allway March 3rd, 2022 Psychedelics, Top News MELBOURNE, Australia, March 3, 2022 /PRNewswire/ — Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for unmet medical needs, today announced it has executed a license agreement with... Read more
Ryan Allway March 2nd, 2022 Psychedelics, Top Story OXFORD, Ohio and COCONUT CREEK, Fla., March 2, 2022 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company“), an integrated and intellectual property driven biotechnology company developing novel, bespoke psychoactive medicinal candidates targeting the potential treatment of... Read more
Cognetivity Neurosciences Closes Final Tranche of Unit Offering
February 25, 2022
Ryan Allway February 25th, 2022 Psychedelics, Top News VANCOUVER, BC, Feb. 24, 2022 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN) (OTCQB: CGNSF) (FWB: 1UB), a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments, is pleased to announce that, further to its... Read more
Silo Wellness Announces Successful Launch of 2022 Psilocybin Retreat Schedule and other Corporate Updates
February 23, 2022
Ryan Allway February 23rd, 2022 Psychedelics, Top News Toronto, Ontario–(Newsfile Corp. – February 23, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company”), a leading global psychedelics company, today announces several corporate updates. On February 4, 2022, the Company completed its first... Read more
Ryan Allway February 17th, 2022 Psychedelics, Top News TORONTO, February 17, 2022–(BUSINESS WIRE)–Biomind Labs Inc. (“Biomind Labs” or the “Company“) (NEO: BMND) (OTC: CRSWF) (FSE: 3XI), a leading biotech company focused on innovation and research on endogenous tryptamines (biomolecules acting as psychoneuroplastogens) for the treatment of mental health disorders and... Read more
Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through its COPE Program with InterVivo Solutions
February 17, 2022
Ryan Allway February 17th, 2022 Psychedelics TORONTO, Feb. 17, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs,... Read more
Neuroplasticity, Psychedelics, and Mental Health
February 17, 2022
Robin Lefferts February 17th, 2022 Psychedelics, Top News The brain is a tangled, incredibly complex mass of about 86 billion neurons. The ability to create new neurons, called neurogenesis, was long thought to stop by the age of 25. There is some debate, however, as one recent study put... Read more
Zollaris Laboratories Corp. Receives Health Canada authorization to investigate PSILOCYBIN (PSYCHEDELIC MUSHROOMS) for potential new therapeutics
February 16, 2022
Ryan Allway February 16th, 2022 Psychedelics, Top News Psilocybin therapy is being investigated by Zollaris for the treatment of mental health and other unmet medical needs HAWKESBURY PROVIDENCE, Ontario, Feb. 16, 2022 /PRNewswire-PRWeb/ — Zollaris Laboratories Corporation. (hereafter, “Zollaris”) receives authorization from the Health Canada, Office of Controlled Substances for analytical investigation of several... Read more
Optimi Health Approved to Supply Psilocybin Under Health Canada’s Special Access Program
February 16, 2022
VANCOUVER, BC (GLOBE NEWSWIRE – February 16, 2022) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to report that Health Canada has added the... Read more
